YER147C-A Antibody

What is YER147C-A protein and why is it significant in research?

YER147C-A is a yeast protein involved in cellular processes related to proteostasis. Recent evidence suggests it may play roles in protein interactions with the proteasome system, potentially through associations with regulatory proteins like Rpn14, which has been shown to interact with other proteins affecting proteasomal degradation . Understanding YER147C-A is particularly important for researchers studying proteostasis pathways, as disruptions in these systems are implicated in numerous cellular dysfunction mechanisms.

The protein's significance stems from its potential involvement in:

• Protein homeostasis regulation

• Potential interactions with proteasomal assembly factors

• Roles in stress response pathways

• Contributions to cellular protein quality control systems

What experimental techniques are most effective for studying YER147C-A?

The following methodological approaches have demonstrated effectiveness in studying YER147C-A:

• Fluorescent protein timers: This technique allows in vivo analysis of protein dynamics and can reveal changes in protein turnover and stability .

• Co-immunoprecipitation assays: Useful for identifying protein-protein interactions involving YER147C-A.

• Cycloheximide chase experiments: These experiments help determine protein half-life and degradation kinetics .

• Western blotting with knockout controls: Essential for confirming antibody specificity and target validation .

• Microscopy techniques: For visualizing cellular localization and potential aggregate formation.

How should researchers validate YER147C-A antibodies before experimental use?

Antibody validation is critical for ensuring experimental reproducibility. For YER147C-A antibodies, proper validation should include:

• Target verification: Confirming the antibody recognizes YER147C-A specifically, ideally using knockout/knockdown controls .

• Application-specific validation: Testing the antibody in the specific experimental context (Western blot, immunofluorescence, etc.) where it will be used .

• Cross-reactivity assessment: Determining whether the antibody binds to proteins other than YER147C-A .

• Experimental condition validation: Verifying the antibody performs as expected under the specific conditions of the planned experiment .

Studies have revealed that approximately 50% of commercial antibodies fail to meet basic standards for characterization, resulting in estimated financial losses of $0.4–1.8 billion annually in the United States alone .

How do YER147C-A antibodies compare in specificity and performance across different applications?

Antibody performance varies significantly across different experimental applications. Based on general antibody characterization studies:

Recent large-scale antibody validation studies have demonstrated that recombinant antibodies outperform both monoclonal and polyclonal antibodies across multiple assays . For YER147C-A research, this suggests recombinant antibodies may offer superior reproducibility, though proper validation remains essential regardless of antibody type.

What controls are essential when using YER147C-A antibodies in different experimental contexts?

Essential controls vary by experimental application but should generally include:

For Western blotting:

• Knockout/knockdown samples (considered superior to other control types)

• Loading controls for normalization

• Positive controls (known samples containing YER147C-A)

• Negative controls (samples without target protein)

For immunofluorescence:

• Knockout cell lines (particularly critical for imaging applications)

• Secondary antibody-only controls

• Peptide competition assays

• Positive and negative tissue/cell controls

For immunoprecipitation:

• Input samples

• Non-specific IgG controls

• Reverse immunoprecipitation when possible

Research has shown that knockout cell lines provide superior control compared to other validation methods, particularly for immunofluorescence applications .

How can researchers distinguish between specific and non-specific binding when using YER147C-A antibodies?

Distinguishing specific from non-specific binding requires rigorous validation:

• Knockout/knockdown validation: The gold standard approach involves comparing antibody signals between wild-type and YER147C-A knockout samples .

• Peptide competition assays: Pre-incubating the antibody with purified YER147C-A protein or peptide should abolish specific signals but not non-specific ones.

• Multiple antibodies approach: Using different antibodies targeting distinct epitopes of YER147C-A can help confirm specificity.

• Signal correlation with expression levels: Specific signals should correlate with known or experimentally manipulated expression levels of YER147C-A.

• Mass spectrometry verification: For immunoprecipitation experiments, mass spectrometry can confirm the identity of pulled-down proteins.

A shocking study revealed that an average of approximately 12 publications per protein target included data from antibodies that failed to recognize the relevant target protein , underscoring the critical importance of proper validation.

What methodologies are most effective for studying YER147C-A interactions with proteasomal components?

Several methodologies have proven effective for studying protein-proteasome interactions that can be applied to YER147C-A research:

• Co-immunoprecipitation (Co-IP): This technique can identify direct interactions between YER147C-A and proteasomal subunits or regulatory factors. Recent studies have successfully used Co-IP to demonstrate interactions between α-synuclein and the Rpt2 proteasome base subunit .

• Yeast two-hybrid screening: This approach can identify novel protein interactions involving YER147C-A.

• Proximity labeling techniques: BioID or APEX2 can identify proteins in close proximity to YER147C-A within cells.

• Fluorescence resonance energy transfer (FRET): This technique can reveal direct protein interactions in living cells.

• Proteasome activity assays: These can determine how YER147C-A affects 26S proteasome function, similar to studies showing decreased 26S activity with increased levels of other proteins .

How can researchers assess the impact of YER147C-A on protein homeostasis?

To assess YER147C-A's impact on protein homeostasis, researchers can employ:

• Tandem fluorescent protein timers: This approach enables in vivo analysis of protein dynamics and can reveal changes in protein turnover upon experimental manipulation of YER147C-A levels .

• High-throughput screening: This method can identify proteins with altered stability upon YER147C-A expression or deletion .

• Cycloheximide chase experiments: These experiments track protein degradation rates and can reveal how YER147C-A affects the stability of specific proteins .

• Ubiquitin conjugate accumulation assays: These assays measure the accumulation of ubiquitinated proteins when YER147C-A levels are altered, similar to studies with other proteins that showed increased ubiquitin conjugates upon proteasome inhibition .

• Phenotypic characterization: Assessing growth, morphology, and stress responses in cells with altered YER147C-A expression can reveal functional impacts on proteostasis .

What role might YER147C-A play in proteasomal degradation pathways?

Based on studies of protein-proteasome interactions, YER147C-A may influence proteasomal degradation through several mechanisms:

• Direct interaction with proteasome subunits: Similar to how α-synuclein interacts with the Rpt2 proteasome base subunit .

• Modulation of proteasome assembly factors: YER147C-A might interact with chaperones like Rpn14, which has been shown to be stabilized upon expression of other proteins .

• Impact on proteasome activity: YER147C-A could affect 26S proteasome activity, similar to how expression of α-synuclein and increased Rpn14 levels result in decreased 26S activity .

• Influence on deubiquitination: YER147C-A might interact with deubiquitinases like Rpn11, which has been shown to be important for protein degradation and cell morphology .

• Effects on substrate recognition: YER147C-A could affect how the proteasome recognizes or processes ubiquitinated substrates.

What are common technical challenges when working with YER147C-A antibodies and how can they be addressed?

Common technical challenges and their solutions include:

• Weak or absent signals:

  • Optimize antibody concentration

  • Try different blocking buffers

  • Increase incubation time or temperature

  • Use signal enhancement systems

• High background:

  • Increase washing steps

  • Use different blocking agents

  • Titrate antibody concentration

  • Pre-adsorb antibody with non-specific proteins

• Inconsistent results across experiments:

  • Use consistent protocols and reagent lots

  • Implement standardized positive controls

  • Consider switching to recombinant antibodies, which show superior consistency

• Cross-reactivity:

  • Validate with knockout/knockdown controls

  • Use peptide competition assays

  • Try different antibodies targeting different epitopes

• Batch-to-batch variability:

  • Purchase larger lots when possible

  • Aliquot and store antibodies properly

  • Consider recombinant antibodies for greater consistency

How can researchers optimize protocols for detecting YER147C-A in different yeast strains or growth conditions?

Protocol optimization for different experimental conditions should consider:

• Strain-specific modifications:

  • Adjust lysis buffers based on cell wall differences

  • Modify extraction protocols for different growth phases

  • Consider fusion tags for difficult-to-detect variants

• Growth condition adaptations:

  • Optimize sample collection timing for stress conditions

  • Adjust protein extraction methods for nutrient-limited cultures

  • Consider fixation methods that preserve condition-specific states

• Expression level considerations:

  • Use more sensitive detection methods for low-abundance conditions

  • Adjust antibody concentrations based on expected expression levels

  • Consider enrichment steps for low-abundance scenarios

• Sample preparation optimization:

  • Test different lysis methods (mechanical, enzymatic, chemical)

  • Evaluate various detergents for membrane-associated forms

  • Optimize centrifugation and clarification steps

• Validation across conditions:

  • Verify antibody performance in each experimental condition

  • Include condition-specific controls

  • Validate with orthogonal detection methods

What emerging technologies might enhance YER147C-A antibody-based research?

Emerging technologies with potential applications in YER147C-A research include:

• Active learning algorithms for experimental design: Novel active learning strategies can improve experimental efficiency in library-on-library settings, reducing the number of required antigen mutant variants by up to 35% and accelerating the learning process .

• Machine learning for binding prediction: ML models can predict antibody-antigen binding by analyzing many-to-many relationships, though challenges remain for out-of-distribution prediction scenarios .

• Advanced validation resources: Projects like YCharOS provide comprehensive antibody validation data, helping researchers select properly characterized antibodies and avoid those with poor specificity .

• Recombinant antibody technologies: These offer superior consistency and performance compared to traditional monoclonal and polyclonal antibodies .

• Proteome-wide characterization approaches: Large-scale efforts to characterize antibodies targeting the entire proteome provide valuable resources for researchers studying specific proteins .

How should researchers address contradictory results obtained with different YER147C-A antibodies?

When faced with contradictory results from different antibodies:

• Evaluate antibody validation: Assess the validation status of each antibody, prioritizing results from antibodies with thorough validation documentation .

• Consider epitope differences: Different antibodies may target distinct epitopes that are differentially accessible in various experimental contexts or protein states.

• Perform orthogonal validation: Use non-antibody-based methods (mass spectrometry, genetic approaches) to confirm results.

• Check for post-translational modifications: Some antibodies may preferentially recognize modified forms of YER147C-A. For example, phosphorylation can significantly impact protein stability and detection, as seen with other proteins .

• Report discrepancies transparently: Publish all results, including contradictory findings, to advance understanding of these discrepancies.

Research has shown that approximately 50-75% of proteins are covered by at least one high-performing commercial antibody, depending on the application , suggesting that identifying properly validated antibodies is possible but requires diligence.

What statistical approaches are recommended for analyzing YER147C-A antibody-based experimental data?

Recommended statistical approaches include:

How can researchers ensure quantitative accuracy when measuring YER147C-A levels or interactions?

To ensure quantitative accuracy:

• Standard curve generation:

  • Use purified recombinant protein for calibration

  • Include standards in each experiment

  • Verify linear range of detection

• Multiple detection methods:

  • Validate key findings with orthogonal techniques

  • Compare results from different antibodies targeting distinct epitopes

  • Combine antibody-based and non-antibody methods

• Internal controls:

  • Include spike-in controls

  • Use consistent positive controls across experiments

  • Implement loading controls appropriate for the experimental condition

• Technical considerations:

  • Verify signal is within the linear range of detection

  • Account for background signal

  • Consider signal saturation in imaging applications

• Validation with genetic approaches:

  • Compare antibody-detected levels with mRNA expression

  • Validate with overexpression and knockdown systems

  • Use knockout controls to establish baseline signals